XNCRのチャート
XNCRの企業情報
| symbol | XNCR |
|---|---|
| 会社名 | Xencor Inc （ゼンコア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ゼンコア（Xencor Inc.）は臨床段階のバイオ医薬品会社である。同社は重篤で生命を脅かす疾病を治療するためにモノクローナル抗体の発見・開発に焦点を当てる。同社は2つのフェーズⅡ試験で自己免疫疾患のために開発されるXmAb5871と、フェーズⅠ試験で喘息のために開発されるXmAb7195の2種類の臨床段階の製品候補を開発する。また、ヘテロ二量体Fc二重特異性技術を用いた二重特異性抗体候補のパイプライン、急性骨髄性白血病（AML）の治療の第I相試験であるXmAb14045、B細胞悪性腫瘍の治療のための第I相試験であるXmAb13676、神経内分泌腫瘍の治療のために前臨床開発中のXmAb18087、および様々な癌の治療のために前臨床開発中であり、その二重チェックポイント阻害剤であるXmAb20717が含まれる。 ゼンコアは、米国のバイオ医薬品会社。癌や自己免疫性炎症疾患の治療のための抗体やタンパク質を開発する。異常細胞を特異的に狙う同社のタンパク質設計の自動化技術の活用により、抗体を開発している。また、他社との提携による臨床抗体プログラムも行う。本社は、カリフォルニア州モンロビア。 Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. |
| 本社所在地 | 111 West Lemon Avenue Monrovia CA 91016 USA |
| 代表者氏名 | Bassil I. Dahiyat Bassil I. Dahiyat |
| 代表者役職名 | President Chief Executive Officer Founder Director |
| 電話番号 | +1 626-305-5900 |
| 設立年月日 | 35643 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | － |
| url | www.xencor.com |
| nasdaq_url | https://www.nasdaq.com/symbol/xncr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -86.59400 |
| 終値（lastsale） | 35.33 |
| 時価総額（marketcap） | 1972336536.96 |
| 時価総額 | 時価総額（百万ドル） 1898.088 |
| 売上高 | 売上高（百万ドル） 18.03000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1642.68 |
| 当期純利益 | 当期純利益（百万ドル） -58.90800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Xencor Inc revenues decreased from $16M to $0K. Net loss increased from $23.2M to $55.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Development - Balancing val increase of 54% to $43.4M (expense) Stock-based Compensation in R&D increase of 62% to $6M (expense). |
XNCRのテクニカル分析
XNCRのニュース
Xencor, Inc. (XNCR) Q4 2022 Earnings Call Transcript 2023/02/24 04:11:08 Seeking Alpha
Xencor, Inc. (NASDAQ:NASDAQ:XNCR) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ETCompany ParticipantsCharles Liles - Head, Corporate Communications and IRBassil Dahiyat -…
Xencor GAAP EPS of -$0.20 beats by $0.60, revenue of $21.6M beats by $2.36M 2023/02/23 21:55:43 Seeking Alpha
Xencor press release (XNCR): Q4 GAAP EPS of -$0.20 beats by $0.60.Revenue of $21.6M (-86.0% Y/Y) beats by $2.36M.Cash, cash equivalents, receivables and marketable debt…
Xencor: Q4 Earnings Snapshot 2023/02/23 21:28:56 WTOP
MONROVIA, Calif. (AP) — MONROVIA, Calif. (AP) — Xencor Inc. (XNCR) on Thursday reported a loss of $12 million in…
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results 2023/02/23 21:01:00 Business Wire
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a review of recent business and clinical highlights. “In 2022, we focused on advancing our internal portfolio of XmAb® drug candidates, including the ongoing Phase 2 studies for vudalima
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 2023/02/16 21:01:00 Business Wire
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after the market closes on Thursday, February 23, 2023. Xencor management will host a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corp
Xencor Earnings Preview 2022/11/04 17:08:36 Benzinga
Xencor (NASDAQ: XNCR ) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here''s what investors need to know before the announcement. Analysts estimate that Xencor will report an earnings per share (EPS) of $-0.68. Xencor bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022 2022/10/31 20:01:00 Business Wire
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and
Is Xencor Inc. (NASDAQ: XNCR) A Good Pick For New Investors Now? 2022/08/27 13:30:00 Stocks Register
Xencor Inc. (NASDAQ:XNCR) shares, rose in value on Friday, 08/26/22, with the stock price down by -6.01% to the previous day’s close as strong demand from buyers drove the stock to $27.85. Actively observing the price movement in the last trading, the stock closed the session at $29.63, falling within a range of $27.55 and … Is Xencor Inc. (NASDAQ: XNCR) A Good Pick For New Investors Now? Read More »
Xencor, Inc. PT Raised to $59 at Mizuho Securities 2022/08/12 09:02:01 Investing.com
https://www.investing.com/news/pro/xencor-inc-pt-raised-to-59-at-mizuho-securities-432SI-2871042
Xencor (XNCR) Investor Presentation - Slideshow 2022/08/11 17:53:15 Seeking Alpha
The following slide deck was published by Xencor, Inc.
Is Xencor Inc. (NASDAQ: XNCR) A Good Pick For New Investors Now? 2022/08/27 13:30:00 Stocks Register
Xencor Inc. (NASDAQ:XNCR) shares, rose in value on Friday, 08/26/22, with the stock price down by -6.01% to the previous day’s close as strong demand from buyers drove the stock to $27.85. Actively observing the price movement in the last trading, the stock closed the session at $29.63, falling within a range of $27.55 and … Is Xencor Inc. (NASDAQ: XNCR) A Good Pick For New Investors Now? Read More »
Xencor, Inc. PT Raised to $59 at Mizuho Securities 2022/08/12 09:02:01 Investing.com
https://www.investing.com/news/pro/xencor-inc-pt-raised-to-59-at-mizuho-securities-432SI-2871042
Xencor (XNCR) Investor Presentation - Slideshow 2022/08/11 17:53:15 Seeking Alpha
The following slide deck was published by Xencor, Inc.
Xencor''s Return On Capital Employed Overview 2022/08/11 15:13:01 Benzinga
Benzinga Pro data, Xencor (NASDAQ: XNCR ) reported Q2 sales of $30.18 million. Earnings fell to a loss of $33.98 million, resulting in a 244.0% decrease from last quarter. In Q1, Xencor earned $23.59 million, and total sales reached $85.50 million. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a … Full story available on Benzinga.com